Literature DB >> 16283219

Survey of neonatal candidiasis in Greece.

J Dotis1, J Evdoridou, G Kremenopoulos, E Roilides.   

Abstract

In order to estimate the extent of neonatal candidiasis in Greece and to identify trends in clinical management, the present study was conducted using a questionnaire directed to Greek neonatologists and pediatric infectious disease specialists. The respondents represented 15 hospitals in the country's seven largest cities, which are currently the only Greek cities with neonatal intensive care units. Based on the responses, the incidence of neonatal candidiasis was determined to be 1.87 and 1.94 cases per unit-year for the years 2001 and 2002, respectively. Although a shift toward the isolation of non-Candida albicans isolates was noted, C. albicans was still the predominant pathogenic species. Deoxycholate amphotericin B remains the most frequently used antifungal agent in neonatal units nationwide.

Entities:  

Mesh:

Year:  2005        PMID: 16283219     DOI: 10.1007/s10096-005-0022-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

Review 1.  Neonatal candidosis: clinical picture, management controversies and consensus, and new therapeutic options.

Authors:  Eugene Leibovitz
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 2.  International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections.

Authors:  J E Edwards; G P Bodey; R A Bowden; T Büchner; B E de Pauw; S G Filler; M A Ghannoum; M Glauser; R Herbrecht; C A Kauffman; S Kohno; P Martino; F Meunier; T Mori; M A Pfaller; J H Rex; T R Rogers; R H Rubin; J Solomkin; C Viscoli; T J Walsh; M White
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

3.  Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia.

Authors:  D E Noyola; M Fernandez; E H Moylett; C J Baker
Journal:  Clin Infect Dis       Date:  2001-04-01       Impact factor: 9.079

4.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

5.  Invasive candidosis in pediatric patients.

Authors:  Emmanuel Roilides; Isaac Kadiltsoglou; Dimitrios Zahides; Evangelia Bibashi
Journal:  Clin Microbiol Infect       Date:  1997-04       Impact factor: 8.067

6.  Should central venous catheters be removed as soon as candidemia is detected in neonates?

Authors:  M G Karlowicz; L N Hashimoto; R E Kelly; E S Buescher
Journal:  Pediatrics       Date:  2000-11       Impact factor: 7.124

7.  Caspofungin therapy of neonates with invasive candidiasis.

Authors:  Carla M Odio; Roberto Araya; Luis E Pinto; Carlos E Castro; Sergio Vasquez; Braulio Alfaro; Alberto Sàenz; Marco L Herrera; Thomas J Walsh
Journal:  Pediatr Infect Dis J       Date:  2004-12       Impact factor: 2.129

Review 8.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

9.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

10.  Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases.

Authors:  E H Kossoff; E S Buescher; M G Karlowicz
Journal:  Pediatr Infect Dis J       Date:  1998-06       Impact factor: 2.129

View more
  1 in total

1.  Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series.

Authors:  A Spiliopoulou; G Dimitriou; E Jelastopulu; I Giannakopoulos; E D Anastassiou; Myrto Christofidou
Journal:  Mycopathologia       Date:  2011-11-11       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.